Angiotensin II AT1-receptor blockade inhibits monocyte activation and adherence in transgenic (mRen2)27 rats

Journal of Cardiovascular Pharmacology

Volumn 33, Issue 3, 1999, Pages 341-351

  Strawn, William B ^a   Gallagher, Patricia E ^a   Tallant, E Ann ^a   Ganten, Detlev ^a   Ferrario, Carlos M ^a  

^a WAKE FOREST SCHOOL OF MEDICINE   (United States)

Author keywords

Angiotensin II; Endothelium; Hypertension; Losartan; Monocyte; TGR(mRen2)27

Indexed keywords

ANGIOTENSIN 2 RECEPTOR; ANGIOTENSIN RECEPTOR ANTAGONIST; HYDRALAZINE; LOSARTAN; ANGIOTENSIN 1 RECEPTOR; ANGIOTENSIN II; ANGIOTENSIN RECEPTOR; ANTIHYPERTENSIVE AGENT; NITROBLUE TETRAZOLIUM; PEPTIDE FRAGMENT;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIHYPERTENSIVE ACTIVITY; ARTICLE; CELL ADHESION; CONTROLLED STUDY; DRUG EFFECT; ENDOTHELIUM CELL; ENDOTHELIUM INJURY; HEMATOCRIT; HYPERTENSION; MONOCYTE; NONHUMAN; PRIORITY JOURNAL; RAT; RECEPTOR BLOCKING; RECEPTOR UPREGULATION; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; SUBCUTANEOUS DRUG ADMINISTRATION; SUBENDOTHELIUM; ANIMAL; BLOOD; BLOOD CELL COUNT; BLOOD PRESSURE; CYTOLOGY; DRUG ANTAGONISM; FEMALE; GENETICS; HEART RATE; MALE; METABOLISM; PATHOLOGY; SPRAGUE DAWLEY RAT; TRANSGENIC ANIMAL; VASCULAR ENDOTHELIUM;

ANGIOTENSIN II; ANIMALS; ANIMALS, GENETICALLY MODIFIED; ANTIHYPERTENSIVE AGENTS; BLOOD CELL COUNT; BLOOD PRESSURE; CELL ADHESION; ENDOTHELIUM, VASCULAR; FEMALE; HEART RATE; HEMATOCRIT; HYDRALAZINE; HYPERTENSION; LOSARTAN; MALE; MONOCYTES; NITROBLUE TETRAZOLIUM; PEPTIDE FRAGMENTS; RATS; RATS, SPRAGUE-DAWLEY; RECEPTOR, ANGIOTENSIN, TYPE 1; RECEPTOR, ANGIOTENSIN, TYPE 2; RECEPTORS, ANGIOTENSIN; RENIN-ANGIOTENSIN SYSTEM;

EID: 0032587380     PISSN: 01602446     EISSN: None     Source Type: Journal    
DOI: 10.1097/00005344-199903000-00001     Document Type: Article

References (76)

1. Alexander RW. Hypertension and the pathogenesis of atherosclerosis: oxidative stress and the mediation of arterial inflammatory response: a new perspective. Hypertension 1995;25:155-61.
2. Ebnet K, Kaldjian EP, Anderson AO, Shaw S. Orchestrated information transfer underlying leukocyte endothelial interactions. Annu Rev Immunol 1996;14:155-77.
3. Bondjers G, Gluckhova M, Hansson GK, Postnov YV, Reidy MA, Schwartz SM. Hypertension and atherosclerosis: cause and effect, or two effects with one unknown cause? Circulation 1991;84:VI-2-16.
4. Faruqui R, DiCorleto P. Mechanisms of monocyte recruitment and accumulation. Br Heart J 1993;69:S19-29.
5. Singhal P, Sagar P, Gupta S, et al. Pressure modulates monocyte migration. Am J Hypertens 1997;10:1297-301.
6. Davies PF, Robotewskyj A, Griem ML, Dull RO, Polacek DC. Hemodynamic forces and vascular cell communication in arteries. Arch Pathol Lab Med 1992;116:1301-6.
7. Malek AM, Izumo S. Molecular aspects of signal transduction of shear stress in the endothelial cell. J Hypertens 1994;12:989-99.
8. Simionescu M, Simionescu N. Proatherosclerotic events: pathobiochemical changes occurring in the arterial wall before monocyte migration. FASEB J 1993;7:1359-66.
9. Bevilacqua MP, Nelson RM, Mannori G, Cecconi O. Endothelial-leukocyte adhesion molecules in human disease. Annu Rev Med 1994;45:361-78.
10. Takahashi M, Ikeda U, Masuyama JI, et al. Monocyte-endothelial cell interaction induces expression of adhesion molecules on human umbilical cord endothelial cells. Cardiovasc Res 1996;32: 422-9.
11. Phillips MI, Speakman E, Kimura B. Levels of angiotensin and molecular biology of the tissue renin angiotensin systems. Regul Peptides 1993;43:1-20.
12. Regitz-Zagrosek V, Neuss M, Holtzmeister J, Warnecke C, Fleck E. Molecular biology of angiotensin receptors and their role in human cardiovascular disease. J Mol Med 1996;74:233-51.
13. 1 receptors in endothelial cells. Br J Pharmacol 1996;118:79-84.
14. Clozel M, Kuhn H, Hefti F, Baumgartner H. Endothelial dysfunction and subendothelial monocyte macrophages in hypertension: effect of angiotensin converting enzyme inhibition. Hypertension 1991;18:132-41.
15. Ferrario CM, Deitch JS, Dean RH, Strawn WB. Hypertension and atherosclerosis: a mechanistic understanding of disease progression. Cardiovasc Risk Factors 1996;6:1-12.
16. Hahn AWA, Jonas U, Büher FR, Resink TJ. Activation of human peripheral monocytes by angiotensin II. FEBS Lett 1994;347: 178-80.
17. Helin K, Stoll M, Meffert S, Stroth U, Unger T. The role of angiotensin receptors in cardiovascular diseases. Ann Med 1997;29: 23-9.
18. Kitazono T, Padgett R, Armstrong M, Tompkins P, Heistad D. Evidence that angiotensin II is present in human monocytes. Circulation 1995;91:1129-34.
19. Gomez R, Norling L, Wilfong N, et al. Leukocytes synthesize angiotensinogen. Hypertension 1993;21:470-5.
20. Foris G, Dezso B, Medgyesi G, Fust G. Effect of angiotensin II on macrophage functions. Immunology 1983;48:277-83.
21. Holtz J, Goetz M. Vascular renin-angiotensin system, endothelial function and atherosclerosis? Basic Res Cardiol 1994;89:171-86.
22. Lee Y, Peng Y, Ding Y, Yen M. Losartan attenuates myocardial ischemia-induced ventricular arrhythmias and reperfusion injury in spontaneously hypertensive rats. Am J Hypertens 1997;10:852-8.
23. 1 receptor antagonism on cardiovascular remodeling in aortic-banded rats. Am J Physiol 1997;272:H2131-8.
24. Hilgers KF, Peters J, Veelken R. Increased vascular angiotensin formation in female rats harboring the mouse Ren-2 gene. Hypertension 1992;19:687-91.
25. Peters J, Hilgers K, Maser-Gluth C, Kreutz R. Role of the circulating renin-angiotensin system in the pathogenesis of hypertension in transgenic rats, TGR(mRen2)27. Clin Exp Hypertens 1996;18: 933-48.
26. Bader M, Ganten D. Transgenic rats: tools to study the function of the renin-angiotensin system. Clin Exp Pharmacol Physiol 1996;3: S81-7.
27. Lee MA, Böhm M, Paul M, Bader M, Ganten U, Ganten D. Physiological characterization of the hypertensive transgenic rat TGR(mREN2)27. Am J Physiol 1996;270:E919-29.
28. Tepel M, Klaus T, Lankemper S, Zidek W. Reduced sodium-proton exchange activity in lymphocytes from transgenic rats. Hypertension 1994;24:357-61.
29. Hansson GK, Chao S, Schwartz SM, Reidy MA. Aortic endothelial cell death and replication in normal and lipopolysaccharide-treated rats. Am J Pathol 1985;121:123-7.
30. Dijkstra C, Dopp E, Joling P, Kraal G. The heterogeneity of mononuclear phagocytes in lymphoid organs: distinct macrophage subpopulations in the rat recognized by monoclonal antibodies ED1, ED2 and ED3. Immunology 1985;54:589-99.
31. Schmid-Schönbein GW, Seiffge D, DeLano F, Shen K, Zweifach B. Leukocyte counts and activation in spontaneously hypertensive and normotensive rats. Hypertension 1991;17:323-30.
32. Mullins J, Peters J, Ganten D. Fulminant hypertension in transgenic rats harbouring the mouse Ren-2 gene. Nature 1990;344:541-4.
33. Moriguchi A, Brosnihan KB, Kumagai H, Ganten D, Ferrario CM. Mechanisms of hypertension in transgenic rats expressing the mouse Ren-2 gene. Am J Physiol 1994;266:R1273-9.
34. Kohara K, Tabuchi Y, Senanayake P, Brosnihan K, Ferrario CM. Reassessment of plasma angiotensin measurement: effects of protease inhibitors and sample handling procedures. Peptides 1991;12: 1135-41.
35. Wikström T, Braide M, Bagge U, Risberg B. NBT reactivity correlates to the distribution of PMNs between rat pulmonary and systemic circulation. Am J Physiol 1995;269:H1195-201.
36. Haraoka S, Shimokama T, Watanabe T. Participation of T lymphocytes in atherogenesis: sequential and quantitative observation of aortic lesions of rats with diet-induced hypercholesterolaemia using en face double immunostaining. Virchows Arch 1995;426:307-15.
37. Hansson GK, Starkebaum GA, Benditt EP, Schwartz SM. Fc-mediated binding of IgG to vimentin-type intermediate filaments in vascular endothelial cell. Proc Natl Acad Sci USA 1984;81:3103-7.
38. Wiener J, Lombardi DM, Su JE, Schwartz SM. Immunohistochemical and molecular characterization of the differential response of the rat mesenteric microvasculature to angiotensin-II infusion. J Vasc Res 1996;33:195-208.
39. Skantze U, Bondjers G, Olofsson B, Pettersson K, Svensson A. Endothelial injury in vivo: a technical and statistical approach to the study of aortic integrity. Am J Physiol 1996;270:H1841-9.
40. Strawn WB, Bondjers G, Kaplan JR, et al. Endothelial dysfunction in response to psychosocial stress in monkeys. Circ Res 1991;68: 1270-9.
41. Schnecke A, Witte K, Lemmas B. Effects of angiotensin II receptor antagonist losartan on 24-hour blood pressure of primary and secondary hypertensive rats. J Cardiovasc Pharmacol 1995;26: 214-21.
42. Lee MA, Böhm M, Kim S, et al. Differential gene expression of renin and angiotensinogen in the TGR(mREN-2)27 transgenic rat. Hypertension 1995;25:570-80.
43. Hansson GK, Schwartz SM. Evidence for cell death in the vascular endothelium in vivo and in vitro. Am J Pathol 1983;112:278-86.
44. Strawn WB, Gallagher PE, Dean RH, Ganten D, Ferrario CM. Endothelial injury in transgenic (mRen2)27 hypertensive rats. Am J Hypertens 1997;10:51-7.
45. Hansson GK, Bondjers G, Nilsson L. Plasma protein accumulation in injured endothelial cells: immunofluorescent localization of IgG and fibrinogen in the rabbit aortic endothelium. Exp Mol Pathol 1979;30:12-26.
46. Hansson GK, Bondjers G, Bylock A, Hjalmarsson L. Ultrastructural studies on the localization of IgG in the aortic endothelium and subendothelial intima of atherosclerotic and nonatherosclerotic rabbits. Exp Mol Pathol 1980;33:302-15.
47. Schwartz SM, Lombardi DM. Effect of chronic hypertension and antihypertensive therapy on endothelial cell replication in the spontaneously hypertensive rat. Lab Invest 1982;6:510-5.
48. Lin S, Hong C, Chang M, Chiang B, Chien S. Increased aortic endothelial cell death and enhanced transendothelial macromolecular transport in streptozotocin-diabetic rats. Diabetologia 1993;36: 926-30.
49. Wu C, Chi J, Jerng J, et al. Transendothelial macromolecular transport in the aorta of spontaneously hypertensive rats. Hypertension 1990;16:154-61.
50. Hansson GK, Lagerstedt E, Bengtsson A, Heideman M. IgG binding to cytoskeletal intermediate filaments activates the complement cascade. Exp Cell Res 1987;170:338-50.
51. Hansson GK, Björnheden T, Bylock A, Bondjers G. Fc-dependent binding of monocytes to areas with endothelial injury in the rabbit aorta. Exp Mol Pathol 1981;34:264-80.
52. Chobanian AV, Alexander RW. Exacerbation of atherosclerosis by hypertension: potential mechanisms and implications. Arch Intern Med 1996;156:1952-6.
53. Munzel T, Kurz S, Rajagopalan S, et al. Hydralazine prevents nitroglycerin tolerance by inhibiting activation of a membrane-bound NADH oxidase. J Clin Invest 1996;98:1465-70.
54. 1 receptors for angiotensin II, inhibits the binding of N-formylmethiolnyl-leucyl-phenylalanine to neutrophil receptors. J Pharmacol Exp Ther 1997;281:624-8.
55. Liu Y, Liu T, McCarron RM, et al. Evidence for activation of endothelium and monocytes in hypertensive rats. Am J Physiol 1996;270:H2125-31.
56. Shen K, DeLano FA, Zweifach BW, Schmid-Schönbein GW. Circulating leukocyte counts, activation, and degranulation in Dahl hypertensive rats. Circ Res 1995;76:276-83.
57. Arndt H, Smith CW, Granger DN. Leukocyte-endothelial cell adhesion in spontaneously hypertensive and normotensive rats. Hypertension 1993;21:667-73.
58. Hernandez-Presa M, Bustos C, Ortego M, et al. Angiotensin-converting enzyme inhibition prevents arterial nuclear factor kappa-B activation, monocyte chemoattractant protein-1 expression, and macrophage infiltration in a rabbit model of early accelerated atherosclerosis. Circulation 1997;95:1532-41.
59. Capers Q, Alexander R, Lou P, et al. Monocyte chemoattractant protein-1 expression in aortic tissues of hypertensive rats. Hypertension 1997;30:1397-402.
60. Suzuki H, Shibata H, Murakami M, et al. Modulation of angiotensin II type 1 receptor mRNA expression in human blood cells: comparison of platelets and mononuclear leukocytes. Endocrinol J 1995;42:15-22.
61. Lijnen P, Fagard R, Petrov V. Cytosolic calcium changes induced by angiotensin II in human peripheral blood mononuclear cells are mediated via angiotensin II subtype 1 receptors. J Hypertens 1997;15:876-86.
62. Kim JA, Berliner JA, Nadler JL. Angiotensin II increases monocyte binding to endothelial cells. Biochem Biophys Res Commun 1996;226:862-8.
63. Gräfe M, Auch-Schwelk W, Zakrzewicz A, et al. Angiotensin II-induced leukocyte adhesion on human coronary endothelial cells is mediated by E-selectin. Circ Res 1997;81:804-11.
64. Ardaillou R. Active fragments of angiotensin II: enzymatic pathways of synthesis and biological effects. Curr Opin Nephrol Hypertens 1997;6:28-34.
65. Kerins DM, Hao Q, Vaughan DE. Angiotensin induction of PAI-1 expression in endothelial cells is mediated by the hexapeptide angiotensin IV. J Clin Invest 1995;96:2515-20.
66. Tallant EA, Lu X, Weiss R, Chappell M, Ferrario CM. Bovine aortic endothelial cells contain an angiotensin-(1-7) receptor. Hypertension 1997;29:388-93.
67. Freeman E, Chisholm G, Ferrario CM, Tallant EA. Angiotensin-(1-7) inhibits vascular smooth muscle cell growth. Hypertension 1996; 28:104-8.
68. Strawn WB, Ferrario CM, Tallant EA. Angiotensin-(1-7) reduces smooth muscle growth after vascular injury. Hypertension 1999 (in press).
69. Tung D, Bjursten L, Zweifach B, Schmid-Schönbein GW. Leukocyte contribution to parenchymal cell death in an experimental model of inflammation. J Leukoc Biol 1997;62:163-75.
70. DeLano F, Forrest M, Schmid-Schönbein GW. Attenuation of oxygen free radical formation and tissue injury during experimental inflammation by P-selectin blockade. Microcirculation 1997;4: 349-57.
71. Collins T, Read M, Neish A, Whitley M, Thanos D, Maniatis T. Transcriptional regulation of endothelial cell adhesion molecules: NF-κB and cytokine-inducible enhancers. FASEB J 1995;9: 899-909.
72. Wang X, Feuerstein G, Clark R, Yue T. Enhanced leucocyte adhesion to interleukin-1β stimulated vascular smooth muscle cells is mainly through intercellular adhesion molecule-1. Cardiovasc Res 1994;28:1808-14.
73. Brasier AR, Li J, Wimbish KA. Tumor necrosis factor activates angiotensinogen gene expression by the Rel A transactivator. Hypertension 1996;27:1009-17.
74. Vicaut E, Rasetti C, Baudry N. Effects of tumor necrosis factor and interleukin-1 on the constriction induced by angiotensin II in rat aorta. J Appl Physiol 1996;80:1891-7.
75. Pitt B, Segal R, Martinez F, et al. Randomised trial of losartan versus captopril in patients over 65 with heart failure (Evaluation of Losartan in the Elderly Study, ELITE). Lancet 1997;349:747-52.
76. Hamroff G, Blaufarb I, Mancini D, et al. Angiotensin II-receptor blockade further reduces afterload safely in patients maximally treated with angiotensin-converting enzyme inhibitors for heart failure. J Cardiovasc Pharmacol 1997;30:533-6.